12.10.2021 SynBiotic SE  DE000A3E5A59

SynBiotic SE plans Canadian cross-listing


DGAP-Media / 12.10.2021 / 10:00

SynBiotic SE plans Canadian cross-listing

Munich, October 12, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77), already listed on the Frankfurt and Düsseldorf stock exchanges, is now to be listed on the Canadian NEO Exchange in Toronto - a new FinTech stock exchange that has been revolutionizing the market since 2014, offering modern services across the capital market. The Board of Directors and the Managing Director have announced passing a corresponding resolution.

Lars Müller, CEO of SynBiotic SE, explains: "Canada is the flagship country when it comes to the cannabis industry. The sector there is particularly well developed, with a number of listed companies and billions in market capitalization. Above all, having our own Canadian listing makes it easier for us to gain access to specialized investors. In the Canadian capital market, we also ensure ourselves of a completely different degree of attention to and understanding of our issue - and can thus better exploit the opportunities to access capital."

All of this would be facilitated by the platform company being in the midst of its peer group on the new NEO Exchange. With the Canadian top dogs Tilray, Canopy Growth or the Cronos Group, a vastly improved comparability to that enjoyed in Europe would follow. Müller continues: "Analysts, market observers and investors will look at us with different eyes - but so will the Canadian competition. Because at the latest, when they further expand into Europe, they will be on the lookout for cooperation partners. Therefore, our envisaged move to go public on the NEO Exchange is also a strategic step."

About SynBiotic SE
SynBiotic SE is the first German listed cannabis company to pursue an EU-focused buy-and-build investment approach. The core business of the platform company is the research and development of new cannabinoid and terpene-based solutions to major social problems such as pain, sleep-disorders and anxiety. In addition, the platform deals with the production of various cannabinoids and develops and distributes pharmaceutical and dietary supplements as well as cosmetic products under its own brands.

End of Media Release

Issuer: SynBiotic SE
Key word(s): Finance

12.10.2021 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: SynBiotic SE
Barer Str. 7
80333 München
E-mail: [email protected]
Internet: https://www.synbiotic.com/
ISIN: DE000A3E5A59
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Tradegate Exchange
EQS News ID: 1239995

End of News DGAP Media

1239995  12.10.2021 


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 0,00 0,00 0,00 0,00 5,45 15,00 0,00
EBITDA1,2 0,00 0,00 0,00 -0,01 -0,71 -0,85 0,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 -13,03 -5,67 0,00
EBIT1,4 0,00 0,00 0,00 -0,01 -0,83 -1,45 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 -15,23 -9,67 0,00
Jahresüberschuss1 0,00 0,00 0,00 -0,01 -0,88 -1,80 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 -16,15 -12,00 0,00
Cashflow1,7 0,00 0,00 0,00 -0,01 -1,26 0,00 0,00
Ergebnis je Aktie8 0,00 0,00 0,00 0,00 -0,15 -2,50 -0,60
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

WKN Kurs in € Einschätzung Börsenwert in Mio. €
A3E5A5 18,920 Halten 69,51
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -172,00
2,73 - 12,76 -97,85
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
0,00 0,00 0,00 05.08.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.09.2021 30.06.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
0,98% -15,37% -35,21% -15,93%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SynBiotic SE  ISIN: DE000A3E5A59 können Sie bei DGAP abrufen

Beteiligungen , A3E5A5 , SBX , XETR:SBX